Cardax is a consumer health company focused on marketing ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health.* Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company’s pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company’s pre-clinical pharmaceutical candidate for macular degeneration.
Astaxanthin is a powerful and safe naturally occurring molecule that mitigates oxidative stress and inflammation to support overall health.*
Cardax aims to build consumer sales with a reduced corporate cost structure to improve operating cash flow and achieve profitability. Cardax may seek to monetize its pharmaceutical assets through licensing or sale. Other strategic alternatives are also under consideration.
Learn more about our commercialization strategy >>
Intellectual Property Portfolio
We have 28 issued patents related to the composition of matter, pharmaceutical compositions, and pharmaceutical uses of our drug candidates as well as many other related molecules that will expire between 2023 and 2028, subject to patent term extensions. We also have filed additional patents to extend patent coverage in the U.S. and worldwide to 2039-2040, with such applications including coverage related to certain cardiovascular uses on the basis of the CHASE clinical trial results as well as coverage related to the composition of matter of CDX-101.
The Cardax Team
Cardax is led by a highly experienced management team.